Foghorn Therapeutics Inc. (FHTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

One of the most iconic Looney Tunes characters, Foghorn Leghorn, has become the star of his own meme on Twitter / X. The meme features Foghorn Leghorn rambling to anime characters in his signature ...

Before sailing off into the sunset from Charleston for the final time this past weekend, the Carnival Sunshine had one final ...

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders’ Hot Stocks on TipRanks >> Read More on FHTX: Foghorn Therapeutics ...

Foghorn Therapeutics on Monday said it is ending independent development of its FHD-286 drug candidate following disappointing results from an early-stage study. Foghorn said the objective ...

Jefferies lowered the firm’s price target on Foghorn Therapeutics (FHTX) to $14 from $18 and keeps a Buy rating on the shares after the company discontinued development of FHD-286 in acute ...

Foghorn Therapeutics has unveiled its strategic roadmap, emphasizing the advancement of its precision therapeutics pipeline, with a particular focus on oncology. The company is progressing ...

Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. Foghorn Therapeutics Inc ...

Foghorn Therapeutics shares are trading lower by 20.2% during Monday's session. The company announced it will discontinue independent development of its FHD-286 program. Foghorn Therapeutics Inc ...

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Foghorn ® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines to treat serious ...

Foghorn Therapeutics (FHTX) has made the decision to discontinue the independent development of FHD-286 in combination with decitabine in patients with relapsed and/or refractory acute myeloid ...